Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.

scientific article published on 12 January 2018

Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10549-017-4648-Z
P698PubMed publication ID29330623

P50authorChangyuan WeiQ89863799
P2093author name stringQixing Tan
P2860cites workAn exploratory test for an excess of significant findingsQ24273224
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsQ40321992
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.Q48212195
P433issue3
P407language of work or nameEnglishQ1860
P304page(s)769-770
P577publication date2018-01-12
P1433published inBreast Cancer Research and TreatmentQ326085
P1476titleComment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers
P478volume168

Reverse relations

Q92783058Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine modelscites workP2860

Search more.